三氧化二砷治疗急性早幼粒细胞白血病的进展  

Progress on the Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide

作　　者：祝洪明[1] 李军民[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院血液科,上海200025

出　　处：《药学与临床研究》2012年第4期277-284,共8页Pharmaceutical and Clinical Research

摘　　要：三氧化二砷(As2O3)用于治疗急性早幼粒细胞白血病(APL)已有20余年,通过特异性降解PML-RARα融合蛋白,As2O3在复发难治和初发APL患者中均获得了较理想的疗效,不良反应较轻,已成为复发难治APL的首选药物。通过进一步临床试验,As2O3有望成为初发APL的一线用药,并可减低甚至取代化疗,使部分APL成为无需化疗而获得治愈的血液学肿瘤。Arsenic trioxide （As2O3） has been used to treat acute promyelocytic leukemia （APL） for over 20 years. It is of high efficacy and minimal adverse effect among both relapsed-refractory and newly diagnosed APL patients by specifically degrading the PML-RARot fusion protein, which makes it the first choice for relapsed and refractory APL. If confirmed by further clinical trials, As2O3 will become a promising front-line therapy for de novo APL, and it will reduce or substitute chemotherapy, thus turning some APL into curable hematologic malignancy without the involvement of chemotherapy.

关 键 词：三氧化二砷 急性早幼粒细胞白血病 疗效 不良反应 一线用药 

分 类 号：R979.1[医药卫生—药品] R733.7[医药卫生—药学]